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ICD Implantation in Patients with Nonischemic Heart Failure
To the Editor: The findings of the Danish Study 
to Assess the Efficacy of ICDs [Implantable Car-
dioverter–Defibrillators] in Patients with Non-
ischemic Systolic Heart Failure on Mortality 
(DANISH) (Sept. 29 issue)1 are important and 
raise doubts about the current strategy of defi-
brillator implantation for the primary prevention 
of sudden cardiac death. The results are not un-
expected. Current recommendations are based 
mainly on the Multicenter Automatic Defibrilla-
tor Implantation Trial II (MADIT-II)2 and the 
Sudden Cardiac Death in Heart Failure Trial 
(SCD-HeFT).3 Since these trials were conducted, 
the treatment of patients with heart failure has 
changed dramatically, with the introduction of 
angiotensin receptor–neprilysin inhibitors; much 
wider use of mineralocorticoid antagonists, beta-
blockers, and statins; and improved coronary re-
vascularization in patients with ischemic cardio-
myopathy. These treatments reduce not only total 
mortality but also specifically the rate of sudden 
cardiac death.4,5 We agree with the comment by 
McMurray in the accompanying editorial that 
trials involving patients at higher risk should be 
considered.6
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